Your browser doesn't support javascript.
Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose.
Filardi, Bruno Andraus; Monteiro, Valter Silva; Schwartzmann, Pedro Vellosa; do Prado Martins, Vivian; Zucca, Luis Eduardo Rosa; Baiocchi, Gabriela Crispim; Malik, Amyn A; Silva, Julio; Hahn, Anne M; Chen, Nicholas F G; Pham, Kien; Pérez-Then, Eddy; Miric, Marija; Brache, Vivian; Cochon, Leila; Larocca, Rafael A; Mendez, Roberto Della Rosa; Bardini Silveira, Douglas; Pinto, Aguinaldo Roberto; Croda, Julio; Yildirim, Inci; Omer, Saad B; Ko, Albert I; Vermund, Sten H; Grubaugh, Nathan D; Iwasaki, Akiko; Lucas, Carolina; Vogels, Chantal B F; Breban, Mallery; Koch, Tobias R; Chaguza, Chrispin; Tikhonova, Irina; Castaldi, Christopher; Mane, Shrikant; De Kumar, Bony; Ferguson, David; Kerantzas, Nicholas; Peaper, David; Landry, Marie L; Schulz, Wade.
  • Filardi BA; Instituto do Cancer Brasil - Unidade de Ribeirão Preto, São Paulo, São Paulo, Brazil.
  • Monteiro VS; Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, São Paulo, Brazil.
  • Schwartzmann PV; Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
  • do Prado Martins V; Intensive Cardiac Unit, Hospital Unimed Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil.
  • Zucca LER; Advanced Research Center - CAPED, Centro Médico Ribeirão Shopping, Ribeirão Preto, São Paulo, Brazil.
  • Baiocchi GC; Instituto do Cancer Brasil - Unidade de Ribeirão Preto, São Paulo, São Paulo, Brazil.
  • Malik AA; Instituto do Cancer Brasil - Unidade de Ribeirão Preto, São Paulo, São Paulo, Brazil.
  • Silva J; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil.
  • Hahn AM; Yale Institute for Global Health, Yale University, New Haven, CT, USA.
  • Chen NFG; Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.
  • Pham K; Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
  • Pérez-Then E; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Miric M; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Brache V; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
  • Cochon L; Ministry of Health, Santo Domingo, Dominican Republic.
  • Larocca RA; Two Oceans in Health, Santo Domingo, Dominican Republic.
  • Mendez RDR; Two Oceans in Health, Santo Domingo, Dominican Republic.
  • Bardini Silveira D; Profamilia, Biomedical Research Department, Santo Domingo, Dominican Republic.
  • Pinto AR; Intensive Cardiac Unit, Hospital Unimed Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil.
  • Croda J; Center of Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Yildirim I; Federal University of Mato Grosso do Sul, Três Lagoas, MS, Brazil.
  • Omer SB; Laboratório de Imunologia Aplicada, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
  • Ko AI; Laboratório de Imunologia Aplicada, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
  • Vermund SH; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Grubaugh ND; Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Brazil.
  • Iwasaki A; Federal University of Mato Grosso do Sul, Campo Grande, Brazil.
  • Lucas C; Yale Institute for Global Health, Yale University, New Haven, CT, USA.
  • Vogels CBF; Department of Pediatric, Section of Infectious Diseases and Global Health, Yale University School of Medicine, New Haven, CT, USA.
  • Breban M; Yale Institute for Global Health, Yale University, New Haven, CT, USA.
  • Koch TR; Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.
  • Chaguza C; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Tikhonova I; Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.
  • Castaldi C; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Mane S; Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brazil.
  • De Kumar B; Department of Pediatric, Section of Infectious Diseases and Global Health, Yale University School of Medicine, New Haven, CT, USA.
  • Ferguson D; Yale School of Public Health, New Haven, CT, USA.
  • Kerantzas N; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Peaper D; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, USA.
  • Landry ML; Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
  • Schulz W; Center for Infection and Immunity, Yale University, New Haven, CT, USA.
Sci Transl Med ; 15(683): eade6023, 2023 02 15.
Article in English | MEDLINE | ID: covidwho-2240695
ABSTRACT
The emergence of the SARS-CoV-2 Omicron sublineages resulted in increased transmission rates and reduced protection from vaccines. To counteract these effects, multiple booster strategies were used in different countries, although data comparing their efficiency in improving protective immunity remain sparse, especially among vulnerable populations, including older adults. The inactivated CoronaVac vaccine was among the most widely distributed vaccine worldwide and was essential in the early control of SARS-CoV-2-related hospitalizations and deaths. However, it is not well understood whether homologous versus heterologous booster doses in those fully vaccinated with CoronaVac induce distinct humoral responses or whether these responses vary across age groups. We analyzed plasma antibody responses from CoronaVac-vaccinated younger or older individuals who received a homologous CoronaVac or heterologous BNT162b2 or ChAdOx1 booster vaccine. All three evaluated boosters resulted in increased virus-specific IgG titers 28 days after the booster dose. However, we found that both IgG titers against SARS-CoV-2 Spike or RBD and neutralization titers against Omicron sublineages were substantially reduced in participants who received homologous CoronaVac compared with the heterologous BNT162b2 or ChAdOx1 booster. This effect was specifically prominent in recipients >50 years of age. In this group, the CoronaVac booster induced low virus-specific IgG titers and failed to elevate neutralization titers against any Omicron sublineage. Our results point to the notable inefficiency of CoronaVac immunization and boosting in mounting protective antiviral humoral immunity, particularly among older adults, during the Omicron wave. These observations also point to benefits of heterologous regimens in high-risk populations fully vaccinated with CoronaVac.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibody Formation Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Aged / Humans Language: English Journal: Sci Transl Med Journal subject: Science / Medicine Year: 2023 Document Type: Article Affiliation country: Scitranslmed.ade6023

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibody Formation Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Aged / Humans Language: English Journal: Sci Transl Med Journal subject: Science / Medicine Year: 2023 Document Type: Article Affiliation country: Scitranslmed.ade6023